#USA #New York #class action lawsuit #Faruqi & Faruqi #Skye Biosciences

Important Update for Skye Investors

Faruqi & Faruqi, LLP, a prominent securities law firm recognized nationally, is currently looking into potential claims against Skye Biosciences, Inc. This investigation is crucial for investors who acquired Skye securities between November 4, 2024, and October 3, 2025. The firm is urging these individuals to reach out as there is an ongoing class action lawsuit with a lead plaintiff deadline set for January 16, 2026.

Background of the Case

Recently, news broke about Skye’s disappointing results from the clinical trials of nimacimab, their flagship product. On October 6, 2025, Skye released data from its Phase 2a clinical trial. Unfortunately, the results were not favorable; the nimacimab monotherapy arm failed to achieve the primary endpoint concerning weight loss when compared to a placebo. These findings not only drew criticism but also caused a significant drop in the company’s stock price, plummeting by $2.85, which equated to a staggering 60% decrease, closing at $1.90 per share.

Faruqi & Faruqi is concerned that Skye and its executives may have violated federal securities laws by potentially making misleading statements about nimacimab’s effectiveness and its clinical prospects. The serious allegations include overstating its effectiveness and misrepresenting its approval and commercial viability, which have led to significant losses for investors.

Investors’ Rights and Actions

The law firm is setting out to assist affected investors by offering legal support and guidance to those interested in joining the class action lawsuit. The role of lead plaintiff is particularly significant; it involves being the primary representative of others in the class, guiding the litigation process. However, it is essential to note that investors can still benefit from any recovery through the class action, even if they choose not to take on the lead role.

For those seeking more information, Faruqi & Faruqi encourages investors, whistleblowers, and former employees with any insights regarding Skye’s operations to come forward. All communications will be handled with confidentiality.

Next Steps for Investors

If you purchased Skye securities during the specified timeframe, you should consider contacting Faruqi & Faruqi directly. Senior Partner James (Josh) Wilson is available for consultations to discuss your legal rights. He can be reached directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Stay informed by checking updates on the class action case through Faruqi & Faruqi’s official website. Additionally, follow their social media channels for real-time updates regarding this matter. Be proactive in safeguarding your investments and ensuring that your voice is heard in this legal process.

In conclusion, the upcoming deadline represents a critical opportunity for investors to engage in securing their financial interests in Skye Biosciences. Don't miss the chance to take action before the January 16, 2026 deadline. Investors must remain vigilant and informed as the case progresses.